Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction非他汀类降脂疗法的进展：心血管风险降低策略演变的叙述性综述
1. 系统已在2025-09-24 09:35:41对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
K Ogunniyi, CC Aghasili, O Akinmoju…
American journal of …
pubmed.ncbi.nlm.nih.govK Ogunniyi, CC Aghasili, O Akinmoju…
美国医学杂志…
pubmed.ncbi.nlm.nih.gov
Despite the well-established benefits of statin therapy in reducing atherosclerotic 尽管他汀类药物在减少动脉粥样硬化方面的益处已得到充分证实cardiovascular disease (ASCVD) risk, many patients fail to achieve recommended low-心血管疾病（ASCVD）风险，许多患者未能达到建议的低风险水平density lipoprotein cholesterol (LDL-C) targets or experience statin intolerance, 低密度脂蛋白胆固醇（LDL-C）目标或存在他汀类药物耐受不良，necessitating alternative approaches. This review examines advances in non-statin lipid-需要采用替代方法。本综述探讨了非他汀类降脂药的最新进展。lowering therapies, focusing on proprotein convertase subtilisin/kexin type 9 (PCSK9) 降压治疗，重点关注前蛋白转化酶枯草溶菌素/Kexin 类型 9（PCSK9）inhibitors (monoclonal antibodies and inclisiran), bempedoic acid, and other non-statin lipid …抑制剂（单克隆抗体和 inclisiran）、贝美匹酯酸以及其他非他汀类脂质药物……
